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We present a case of a patient with malignant melanoma of the glans penis and urethra, which was found in a 53-year-old
man with nonhealing ulcerative penile lesion and bilateral, clinically palpable inguinal lymphadenopathies at diagnosis. A
diagnostic biopsy showed the characteristics of a melanoma. We treated the patient with total penectomy and
bilateral inguinal lymph node dissection. After surgery, chemotherapy with bleomycin, vincristine and cisplatin
and immunotherapy with thymosin injection were started. No recurrence or metastasis occurred during the
3 years after the operation. Melanoma of the penis is very rare, and early diagnosis is important because the patient
prognosis is very poor.
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Malignant melanoma of the penis is an extremely rare
malignancy that accounts for less than 2% of all primary
penile malignant lesions [1]. They are located on the
glans penis (55%), prepuce (28%), penile shaft (9%) and
urethral meatus (8%) [2]. Malignant melanoma of the
penis and urethra as comorbid presentations are more
rare. We present a case of a patient with multifocal mel-
anoma of both the glans penis and urethra, which, to
the best of our knowledge, has not been previously de-
scribed. We also provide a review of the literature, with
emphasis on the pathogenesis and treatment of melan-
oma of the penis and urethra.
Case presentation
A 53-year-old man presented to our institution in 2009
with a 24-month history of difficulty in urinating and a
6-year history of melanin pigmentation of the glans
penis. He did not have a family history of malignant
melanoma. He had experienced urethral orifice suffusion
after sex during the preceding 4 months. His physical
examination revealed patchy erythema melanin pigmen-
tation that was scattered in the glans penis and coronary
sulcus and involved the urethral meatus (Figure 1A).* Correspondence: weiqiang765@126.com
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through urinary cystoscopy. We performed a punch bi-
opsy in two different sites: the glans penis and urethra.
His histopathological examination revealed a malignant
melanoma. Computed tomographic scans of the head,
chest and abdomen were negative for metastatic disease.
There was no palpable inguinal lymphadenopathy. Total
penectomy and bilateral inguinal lymph node dissection
were performed. The penis was cut open longitudinally,
and we found 8-cm melanin pigmentation in the pendu-
lous urethra (Figure 1B). Pathological sections showed
that the malignant melanoma invaded into superficial
muscular layer. Histologic examination of these speci-
mens revealed positive staining with hematoxylin
(Figure 2A), HMB-45 (Figure 2B) and CD68 (Figure 2C).
Bilateral inguinal lymph node specimens were negative.
After surgery, the patient was started on an 8-week course
of chemotherapy with bleomycin, vincristine and cisplatin
and immunotherapy with thymosin injection. The patient
had no tumor recurrence at the 2-year follow-up and re-
mains alive to date.Discussion
Melanoma of the penis is rare [3]. It is a disease of the
elderly, with a peak incidence in the 50- to 70-year-old
age group. The peak incidence of cutaneous melanomas
in other areas of the body occurs in patients 40 to
49 years of age [1,4]. Because melanoma can metastasizehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Multifocal melanoma of both the glans penis and
urethra. (A) Uniform dark brown pigmented macule partially
occupying the glans penis, coronary sulcus and urethral meatus.
(B) Longitudinal incision of the penis showed 8-cm melanin
pigmentation in the pendulous urethra.
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ous tumors. The 2- and 5-year overall survival rates are
63% and 31%, respectively [4]. In several studies, re-
searchers have reported melanoma of both the penis and
the urethra. However, melanoma of the urethra is less
rare than that of the penis. Involvement of the urethra
occurs most frequently in the fossa navicularis. It occurs
less often in the pendulous, bulbous and prostatic areas
[5]. In our patient, melanomas were found in the penis
and urethra at the same time.
Prediction of the clinical course of melanoma is based
mainly on tumor thickness. However, the assessment of
tumor thickness alone is not enough; other important
factors in the prognosis are the tumor’s extent of in-
volvement of local structures and whether there is clin-
ical or histopathological evidence of metastases in the
inguinal or pelvic lymph nodes [4]. Adverse prognostic
factors are thickness (≥3.5 mm), ulceration and diameter
(≥15 mm) [6].
Early diagnosis is of importance because the risk of
distant metastases is high [7]. Melanoma is potentially
curable if the pathological characteristics are favorableFigure 2 Histologic specimens. (A) Numerous atypical melanocytic cells
melanocytes were arranged in nests (hematoxylin and eosin stain; original
strong positive staining for HMB-45 (original magnification, ×200). (C) Secti
The melanocytes were arranged in nests (original magnification, ×200).[8], but penile melanomas are usually diagnosed late.
Clinically, they may vary in presentation from macules
to papules and nodules, all of varying color. The absence
of symptoms, the low level of public awareness and the
difficulty associated with treatments at this site, as well
as—not least in importance—embarrassment at being
examined, all contribute to the delay in diagnosis [6].
Therefore, clinicians should be highly suspicious when
examining any penile pathology. In clinical practice, we
found that it was very difficult to recognize a pigmented
penile lesion as a melanoma. Some authors have re-
ported that dermoscopy is helpful for distinguishing a
melanocytic lesion from a nonmelanocytic one and
can play a role in establishing whether a melanocytic
lesion is benign or malignant, which will improve the
diagnosis [6,9].
Staging of the disease, the choice of treatment and the
patient’s prognosis have traditionally been based on a
system developed by Bracken et al., with stage I disease
confined to the penis, stage II being metastatic to the re-
gional lymph nodes and stage III representing dissemi-
nated disease [10]. Treatment of melanoma of the glans
penis and urethra is surgical, but the main area of con-
troversy lies with the extent of surgery for localized dis-
ease. Some authors [10,11] believe in an aggressive
surgical approach with total amputation of the penis and
bilateral ilioinguinal node dissection. Recently, however,
most authors [12,13] have recommended wide local ex-
cision or distal amputation without lymph node dissec-
tion for lesions. Their rationale is that radical surgery
may be overtreatment because it carries no survival ad-
vantage for stage II or III patients.
The prognosis for patients with melanoma is poor be-
cause of the lack of effective systemic chemotherapy.
Combination chemotherapy consisting of six cycles of
dacarbazine, carmustine, cisplatin and tamoxifen gives
the best results. An overall response rate of about 45%
and a complete response rate of 12% to 14% have beenwith large hyperchromatic nuclei and abundant cytoplasm. The
magnification, ×200). (B) Sections of the main tumor mass show
ons of the main tumor mass show strong positive staining for CD68.
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melanoma can be cured [14,15]. In one study [16], re-
searchers reported that treatment with high doses of ad-
juvant interferon in patients with high-risk stage II and
stage III melanoma reduced the risk of disease recur-
rence and increased the median disease-free survival. In
our patient, we started adjuvant therapy with thymosin
and bleomycin, vincristine and cisplatin, without inter-
feron. The prognosis for our patient is very good, and he
remains alive to date.
Conclusions
We think that early detection was the key to effective
treatment of our patient. In such patients, early recogni-
tion, early and appropriate aggressive surgical therapy
and the development of effective adjuvant therapy are
important elements of improving the prognosis.
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